Margaret Christine Snead1, Jeffrey Wiener1, Sinmisola Ewumi2, Christi Phillips3, Lisa Flowers1, Tina Hylton-Kong4, Natalie Medley-Singh5, Jennifer Legardy-Williams6, Elizabeth Costenbader7, John Papp3, Lee Warner1, Carolyn Black8, Athena P Kourtis1. 1. Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 2. Albert Einstein College of Medicine, Bronx, New York, USA. 3. Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 4. Epidemiology Research and Training Unit, MOH, Kingston, Jamaica. 5. University Hospital of the West Indies, Kingston, Jamaica. 6. Office of Science and Integrated Services, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 7. Family Health International (FHI 360), Durham, North Carolina, USA. 8. Division of Scientific Resources, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Abstract
BACKGROUND: There is limited information on rates of STIs in Jamaica due to syndromic management and limited aetiological surveillance. We examined the prevalence of Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Trichomonas vaginalis (TV) and characteristics associated with STIs among sexually active women who participated in a randomised trial of a progestin implant initiation in Jamaica (the Sino-Implant Study (SIS)). METHODS: SIS was a randomised trial conducted in Kingston, Jamaica, from 2012 to 2014 to evaluate whether initiation of the Sino-Implant (II) led to more unprotected sex among women ages 18-44 years. Data collected included self-reported demographic, sexual behaviour information; and vaginal swabs collected at baseline, 1-month and 3-month follow-up visits for a biomarker of recent semen exposure (prostate-specific antigen (PSA)) and for STIs. We examined associations between STIs and PSA, demographics, sexual behaviour and insertion of an implant, with a repeated-measures analysis using generalised estimating equations (SAS Institute, V.9.3). RESULTS:Remnant vaginal swabs from 254 of 414 study participants were tested for STIs. At baseline, 29% of participants tested for STIs (n=247) had laboratory-confirmed CT, 5% NG, 23% TV and 45% any STI. In a repeated-measures analysis adjusted for study arm (immediate vs delayed implant insertion), those with PSA detected did not have an increased prevalence of any STI (prevalence ratio (PR)=1.04 (95% CI 0.89 to 1.21)), whereas prevalence decreased for each 1-year increase in age (PR=0.98 (95% CI 0.97 to 0.99)). Immediate implant insertion was not associated with increases in any STI in subsequent visits (PR=1.09 (95% CI 0.94 to 1.27)). CONCLUSIONS: Although the prevalence of laboratory-confirmed STIs was high, the immediate initiation of a contraceptive implant was not associated with higher STI prevalence rates over 3 months. TRIAL REGISTRATION NUMBER: NCT01684358. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
RCT Entities:
BACKGROUND: There is limited information on rates of STIs in Jamaica due to syndromic management and limited aetiological surveillance. We examined the prevalence of Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Trichomonas vaginalis (TV) and characteristics associated with STIs among sexually active women who participated in a randomised trial of a progestin implant initiation in Jamaica (the Sino-Implant Study (SIS)). METHODS: SIS was a randomised trial conducted in Kingston, Jamaica, from 2012 to 2014 to evaluate whether initiation of the Sino-Implant (II) led to more unprotected sex among women ages 18-44 years. Data collected included self-reported demographic, sexual behaviour information; and vaginal swabs collected at baseline, 1-month and 3-month follow-up visits for a biomarker of recent semen exposure (prostate-specific antigen (PSA)) and for STIs. We examined associations between STIs and PSA, demographics, sexual behaviour and insertion of an implant, with a repeated-measures analysis using generalised estimating equations (SAS Institute, V.9.3). RESULTS: Remnant vaginal swabs from 254 of 414 study participants were tested for STIs. At baseline, 29% of participants tested for STIs (n=247) had laboratory-confirmed CT, 5% NG, 23% TV and 45% any STI. In a repeated-measures analysis adjusted for study arm (immediate vs delayed implant insertion), those with PSA detected did not have an increased prevalence of any STI (prevalence ratio (PR)=1.04 (95% CI 0.89 to 1.21)), whereas prevalence decreased for each 1-year increase in age (PR=0.98 (95% CI 0.97 to 0.99)). Immediate implant insertion was not associated with increases in any STI in subsequent visits (PR=1.09 (95% CI 0.94 to 1.27)). CONCLUSIONS: Although the prevalence of laboratory-confirmed STIs was high, the immediate initiation of a contraceptive implant was not associated with higher STI prevalence rates over 3 months. TRIAL REGISTRATION NUMBER: NCT01684358. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Entities:
Keywords:
CHLAMYDIA INFECTION; CONTRACEPTION; GONORRHOEA; TRICHOMONAS; WOMEN
Authors: Roxanne Jamshidi; Ana Penman-Aguilar; Jeffrey Wiener; Maria F Gallo; Jonathan M Zenilman; J H Melendez; Margaret Snead; Carolyn M Black; Denise J Jamieson; Maurizio Macaluso Journal: Contraception Date: 2013-08-14 Impact factor: 3.375
Authors: Marion W Carter; Althea Bailey; Margaret C Snead; Elizabeth Costenbader; Malene Townsend; Maurizio Macaluso; Denise J Jamieson; Tina Hylton-Kong; Lee Warner; Markus J Steiner Journal: AIDS Behav Date: 2013-02
Authors: Maria F Gallo; Markus J Steiner; Lee Warner; Tina Hylton-Kong; J Peter Figueroa; Marcia M Hobbs; Frieda M Behets Journal: Sex Transm Dis Date: 2007-10 Impact factor: 2.830
Authors: Jennifer L Evans; Marie-Claude Couture; Ellen S Stein; Neth Sansothy; Lisa Maher; Kimberly Page Journal: Sex Transm Dis Date: 2013-06 Impact factor: 2.830
Authors: Eve Rose; Ralph J Diclemente; Gina M Wingood; Jessica McDermott Sales; Teaniese P Latham; Richard A Crosby; Jonathan Zenilman; Johan Melendez; James Hardin Journal: Arch Pediatr Adolesc Med Date: 2009-01
Authors: Janet E Rosenbaum; Jonathan Zenilman; Johan Melendez; Eve Rose; Gina Wingood; Ralph DiClemente Journal: Sex Transm Infect Date: 2014-03-13 Impact factor: 3.519
Authors: Alexandra M Minnis; Markus J Steiner; Maria F Gallo; Lee Warner; Marcia M Hobbs; Ariane van der Straten; Tsungai Chipato; Maurizio Macaluso; Nancy S Padian Journal: Am J Epidemiol Date: 2009-09-09 Impact factor: 4.897
Authors: Yasaman Zia; Jeffrey Wiener; Margaret Christine Snead; John Papp; Christi Phillips; Lisa Flowers; Natalie Medley-Singh; Elizabeth C Costenbader; Tina Hylton-Kong; Athena P Kourtis Journal: BMJ Open Date: 2018-04-13 Impact factor: 2.692
Authors: MacKinsey A Christian; Maureen Samms-Vaughan; MinJae Lee; Jan Bressler; Manouchehr Hessabi; Megan L Grove; Sydonnie Shakespeare-Pellington; Charlene Coore Desai; Jody-Ann Reece; Katherine A Loveland; Eric Boerwinkle; Mohammad H Rahbar Journal: J Autism Dev Disord Date: 2018-08